KIF20A Predicts Poor Survival of Patients and Promotes Colorectal Cancer Tumor Progression through the JAK/STAT3 Signaling Pathway

Qi Zhang,1 Jun Di,1 Zhiyu Ji,2 Aoning Mi,2 Quanying Li,2 Xianghui Du,1 Anpeng Wang,1 Anlian Wang,1 and Changjiang Qin 2,3

1Department of General Surgery, People’s Hospital of Kaifeng, Kaifeng, China
2Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, China
3Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Correspondence should be addressed to Changjiang Qin; qincj888@163.com

Copyright © 2020 Qi Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kinesin family member 20A (KIF20A) has been recently reported to be upregulated and associated with increased invasiveness and metastasis in several malignancies. However, the role of KIF20A in colorectal cancer (CRC) is still unclear. This study is aimed at investigating the potential roles of KIF20A in the development of CRC. The results of bioinformatics analysis, immunohistochemical staining, and Western blot analysis showed that KIF20A was overexpressed in CRC tissues compared with adjacent normal tissues. High expression of KIF20A in CRC tissues was associated with depth of invasion, lymphatic node metastasis, distant metastasis, and TNM stage. Moreover, the Kaplan-Meier survival analysis showed that CRC patients with high KIF20A expression had poor prognoses. Cox regression analysis revealed that KIF20A was an independent prognostic factor in patients with CRC. Further studies suggested that knockdown of KIF20A was able to reduce cell proliferation and migration by inhibiting the JAK/STAT3 pathway. Taken together, we propose that KIF20A plays a critical role in the tumorigenesis and tumor progression of colorectal cancer and could represent a potential therapeutic target for CRC.

1. Introduction

Colorectal cancer (CRC) is one of the most common digestive system malignancies in the world and is associated with poor overall survival due to its high incidence and mortality rates [1]. In 2016, approximately 134,490 people in the United States were found to have CRC [2]. In the latest statistics from 2018, CRC ranked third in new cases of malignant tumors in both males and females but second in terms of mortality [3, 4]. Despite rapid advances in CRC screening, the detection rate of early CRC patients has not improved satisfactorily. Approximately 25% of CRC patients have metastases at the time of diagnosis. Furthermore, approximately 50% of CRC patients will develop metastasis, thereby contributing to the high mortality of CRC [5]. Therefore, studying the molecular mechanisms underlying the invasion and metastasis of CRC is of great significance for the prevention and treatment of CRC and for improving the long-term survival rate of patients.

Kinesins are a superfamily of motor proteins that have ATP enzyme activity. They are involved in the normal biological activities of various cells, including mitosis, meiosis, and intracellular vesicle transport [6, 7]. Kinesin family member 20A (KIF20A, also known as MKLP2) is located on chromosome 5q31.2 and plays an important role in the dynamics of the Golgi apparatus, it was first named Rab6-binding kinesin (RAB6KIFL) [8, 9]. Recently, several studies have demonstrated that KIF20A
may play an important role in the development and progression of many different types of cancer, including melanoma [10], breast cancer [11, 12], nasopharyngeal cancer [13], pancreatic cancer [14–16], hepatocellular carcinoma [17], and lung cancer [18, 19]. Therefore, KIF20A is regarded as a novel tumor-associated gene. However, the expression and role of KIF20A in CRC have not yet been examined. The aim of this study was to investigate the roles and underlying mechanism of KIF20A in the progression of CRC.

2. Materials and Methods

2.1. Patients and Tissue Specimens. A total of 105 paraffin samples (including CRC tissues and their matched adjacent tissues) were obtained from CRC patients who underwent surgery at the Department of General Surgery, the First Affiliated Hospital of Sun Yat-sen University (FAHSYSU), in 2011. All specimens were pathologically confirmed at the Cancer Center of the First Affiliated Hospital of Sun Yat-sen University. The clinical characteristic data of all patients are shown in Table 1. None of these patients received preoperative chemotherapy or radiotherapy. Histological tumor grade and stage were determined using the eighth edition of the American Joint Committee on Cancer (AJCC) staging system [20]. All patients were followed up. The time of follow-up was up to December 2017. Fresh tissue specimens (including CRC tissues and their matched adjacent tissues) were obtained from CRC patients who underwent surgery at the Department of General Surgery, Huaihe Hospital of Henan University. This study was approved by the Ethics Committees, and written informed consent was obtained from each patient. After collection, all tissues were immediately snap-frozen in liquid nitrogen and stored at -80°C until they were used for investigation.

2.2. Bioinformatics Analysis of TCGA Databases. We applied FireBrowse (http://firebrowse.org/) to retrieve KIF20A expression in cancer and normal tissues in different cohorts in The Cancer Genome Atlas (TCGA). All available CRC mRNA expression data from TCGA-CRC were downloaded from UCSC Xena (https://xenabrowser.net/). Gene expression data, including a total of 380 tumor tissue samples compared to 50 nontumor samples, were used in this study. Excel 2016 and GraphPad Prism 6.0 software were used for log₂ transformation and data analysis.

2.3. Immunohistochemical (IHC) Staining. Immunohistochemical (IHC) staining was performed as previously described, and the method description partly repeats their wording [21]. Formalin-fixed, paraffin-embedded (FFPE) CRC tissues and their matched adjacent tissues from 105 CRC patients were serially sectioned into 4 μm thick slices. In detail, the sections were dewaxed in xylene and rehydrated in a graded alcohol series. The cells were placed in 3% hydrogen peroxide for 10 minutes to inhibit endogenous peroxidase activity and then washed with PBS. Next, antigen retrieval was performed in citrate buffer (pH 6.0) using a microwave. The samples were immersed in 5% fetal bovine serum (FBS) at room temperature for 20 minutes to block nonspecific binding sites. Then, the slides were incubated with a rabbit polyclonal anti-KIF20A antibody (1:100, Abcam, USA, ab104118) at 4°C overnight and washed three times with phosphate-buffered saline (PBS) for 5 minutes. After this, the sections were incubated with biotinylated secondary antibodies at room temperature for 1 h and washed three times with PBS for 5 minutes. Finally, the slides were

Table 1: Correlation between KIF20A expression and clinicopathological variables in 105 CRC patients.

| Characteristics | Total | KIF20A expression | χ² value | P value |
|-----------------|-------|-------------------|---------|--------|
|                 |       | Low (N = 38)      | High (N = 67) |       |
| Gender          |       |                   |         |        |
| Male            | 65    | 28                | 37      |        |
| Female          | 40    | 10                | 30      |        |
| Age             |       |                   |         |        |
| <60 years       | 46    | 16                | 30      |        |
| ≥60 years       | 59    | 22                | 37      |        |
| Tumor size      |       |                   |         |        |
| <5 cm           | 55    | 22                | 33      |        |
| ≥5 cm           | 50    | 16                | 34      |        |
| Differentiation degree |       |                   |         |        |
| Well            | 2     | 0                 | 2       |        |
| Moderate        | 84    | 31                | 53      |        |
| Poor            | 19    | 7                 | 12      |        |
| Tumor location  |       |                   |         |        |
| Ascending colon | 19    | 8                 | 11      |        |
| Transverse colon | 6    | 2                 | 4       |        |
| Descending colon | 2    | 0                 | 2       |        |
| Sigmoid colon   | 24    | 9                 | 15      |        |
| Rectum          | 54    | 19                | 35      |        |
| T stage         |       |                   |         |        |
| 1               | 1     | 1                 | 0       |        |
| 2               | 16    | 11                | 5       |        |
| 3               | 83    | 26                | 57      |        |
| 4               | 5     | 0                 | 5       |        |
| N stage         |       |                   |         |        |
| 0               | 59    | 29                | 30      |        |
| 1               | 31    | 8                 | 23      |        |
| 2               | 15    | 1                 | 14      |        |
| M stage         |       |                   |         |        |
| 0               | 91    | 37                | 54      |        |
| 1               | 14    | 1                 | 13      |        |
| TNM stage       |       |                   |         |        |
| I               | 15    | 11                | 4       |        |
| II              | 40    | 18                | 22      |        |
| III             | 36    | 8                 | 28      |        |
| IV              | 14    | 1                 | 13      |        |
developed with DAB and counterstained with hematoxylin. Protein staining was evaluated via microscopic examination.

All sections were reviewed and scored independently by two pathologists of the Cancer Center. To determine IHC expression of KIF20A in tissues, we applied a scoring system based on the staining intensity and the percentage of positively stained tumor cells. The staining intensity (SI) was graded according to the following criteria: 0, no staining; 1, weak staining; 2, moderated staining; and 3, strong staining. The percentage of positive tumor cells among the total observed cells was scored in five randomly selected fields as follows: 0, no positive tumor cells; 1, 25% positive tumor cells or less; 2, 25% to 50% positive tumor cells; 3, 50% to 75% positive tumor cells; and 4, more than 75% positive tumor cells. In the statistical analysis, the final staining index (SI) was evaluated by multiplying the percentage of positive tumor cells and staining scores as described by Wang et al. [22]. In view of this method, sections with an SI ≥ 4 were counted as high KIF20A expression, and those with an SI < 4 were counted as low KIF20A expression.

2.4. Cell Lines. Human CRC cell lines (HCT116, SW480, SW1116, LOVO, and LS174T) used in the current study were obtained from the First Affiliated Hospital of Sun Yat-sen University (FAHYSU). These cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, Biological Industries, USA) supplemented with 10% fetal bovine serum (FBS, Biological Industries, USA) and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). All cells were cultured in a humidified atmosphere of 5% CO₂ at 37°C for future use.

2.5. KIF20A Small Interfering RNA Transfection. To further explore the role of KIF20A expression in tumor proliferation and migration, cells were transfected with siRNA purchased from Ruibo (Guangzhou, China). The transfections of siRNA were performed using Lipofectamine™ 3000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's guidelines. After 48 h, the cells were cultured to 90% confluence for subsequent analysis.

2.6. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). To detect the expression levels of KIF20A in CRC cell lines, quantitative real-time polymerase chain reaction analysis was performed. Total RNA from cell lines was extracted using TRIzol reagent (Servicebio, Boston, Massachusetts, USA), and complementary DNA (cDNA) was extracted by using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer's recommendations for users. The primer sequences were designed as follows: GAPDH: (forward) 5′-ACTTTGGTATCGTGGAAGGACTCAT-3′ and (reverse) 5′-GTTTTTCTAGACGGCAGGTCAGG-3′; KIF20A: (forward) 5′-ATCAAAATGGCAATCCCTATGTG-3′ and (reverse) 5′-TCTGGTTCCTTTACGCCACCTTTTT-3′. The expression of KIF20A was analyzed using FastStart Universal SYBR Green Master (Roche, Switzerland).

2.7. Western Blotting. Western blotting was performed as described previously [23]. Total proteins were extracted with radioimmunoprecipitation assay (RIPA) buffer supplemented with 1% phenylmethanesulfonyl fluoride (PMSF). The protein concentrations were quantified using a BCA Protein Assay Kit (Solarbio, Beijing, China). Equal concentrations were separated by 10% SDS-PAGE and electrotransferred to PVDF membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk in TBS-T for 1 h at room temperature. Then, the blots were incubated with primary antibodies against human KIF20A (1:500, Proteintech, Wuhan, China) and β-actin (1:3000, Sigma-Aldrich, USA) overnight at 4°C and then with rabbit or mouse secondary antibodies for 1 hour at room temperature after being washed with TBS-T. After washing, the ECL Western Blot Kit (CWbio, Beijing, China) was used to detect the specific bands.

2.8. CCK-8 Array. To further identify the role of KIF20A expression levels on cell proliferation, we used Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Rockville, MD, USA) to measure cell proliferation according to the manufacturer’s instructions. For cell proliferation, after transfection for 48 h, cells were harvested and seeded into 96-well plates at a density of 2000 cells per well. At 0 h, 24 h, 48 h, 72 h, and 96 h, 10 μl CCK-8 kit reagent and 90 μl DMEM without 10% FBS were added to each well, and the cells were cultured for 4 hours in a humidified atmosphere of 5% CO₂ at 37°C. The absorbance of each well at a wavelength of 450 nm (450 nm OD value) was measured using a microplate reader. All data were analyzed with GraphPad Prism 6.0 software.

2.9. Transwell Invasion Assay. Transwell chambers (8 μm pores, Corning, USA) were used in 24-well plates to detect cell invasion. After 48 hours of transfection, first, the chambers were placed in 24-well plates containing 500 μl DMEM without 10% FBS in the lower chamber and 100 μl DMEM in the upper for 30 minutes to hydrate chambers; 3 × 10⁵ cells were diluted in 100 μl serum-free DMEM and seeded into the upper chamber of the 24-well plates. Next, 500 μl DMEM with 10% FBS was added to the lower chamber as a chemoattractant. After 24 h of incubation in 5% CO₂ at 37°C, the cells on the upper surface of the chambers were removed by scraping with a cotton swab, and the cells that migrated to the lower membrane were fixed with 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet. We chose five random fields to photograph and count.

2.10. Wound Healing Assay. A total of 3 × 10⁵ transfected cells were seeded into 6-well plates until they reached 70-80% confluence. The confluent cell layer was wounded by a 10 μl pipette tip. Then, the cells were washed with sterile PBS, and 2 ml fresh medium without FBS was added to every well. The wound healing process was observed at 0 h and 48 h to evaluate the migration ability of the tested cells.

2.11. Statistical Analysis. All data were analyzed using SPSS 19.0 (IBM, USA) software, and all figures were generated using GraphPad Prism 6.0 software. Analysis of the
relationship between the expression of KIF20A in CRC tissues and clinicopathological features of patient tumor progression was carried out using $\chi^2$ tests. The survival curves were evaluated using Kaplan-Meier survival curves and analyzed by the log-rank test. Univariate and multivariate analyses were performed using Cox regression analysis. All differences were considered to be statistically significant at $P < 0.05$.

3. Results

3.1. Expression of KIF20A in CRC Tissues. To identify the expression level of KIF20A in CRC, we analyzed TCGA cohort datasets, and our results showed that the mRNA expression level of KIF20A was upregulated in unpaired CRC tissues ($n = 380$) compared to normal tissues ($n = 50$, Figure 1(a), $P < 0.001$). The mRNA expression level of KIF20A in the paired CRC tissues was significantly upregulated compared with that in the adjacent normal tissues ($n = 32$, Figure 1(b), $P < 0.001$). As shown in Table 2, the results showed that the expression level of KIF20A exhibited a similar trend in other CRC cohorts from the Oncomine database [24–30]. We found that the protein level of KIF20A was higher in tumor tissues than in normal tissues from our medical center, as determined by Western blotting ($n = 8$, Figure 1(c)).

3.2. Overexpression of KIF20A Is Associated with the Clinical Characteristics and Prognosis of CRC Patients. To evaluate the protein expression of KIF20A in human CRC tumor tissues and adjacent normal tissues, we analyzed KIF20A protein expression in paraffin-embedded human CRC specimens by IHC. Figures 2(a) and 2(b) are representative KIF20A IHC stainings. As shown, positive staining signals of KIF20A were mainly distributed in the cytoplasm of cells. The results showed that 67 patients (64%) had significantly higher expression in CRC tissues, and 38 patients (36%) had lower expression or negative expression ($P < 0.05$).

The associations between KIF20A expression level and clinical data of CRC patients were analyzed by $\chi^2$ tests. Our study results revealed that high expression of KIF20A was significantly associated with advanced T stage ($P = 0.005$), N stage ($P = 0.003$), M stage ($P = 0.015$), and TNM stage ($P < 0.001$) (Table 1). Kaplan-Meier survival analysis and log-rank test were carried out to estimate the prognostic significance of KIF20A expression level in CRC patients. We found that high KIF20A expression was associated with worse overall survival (OS) and disease-free survival (DFS) than low KIF20A expression ($P < 0.001$, Figures 2(c) and 2(d)).

Moreover, univariate and multivariate analyses were used to compare the impact of KIF20A expression and other prognostic parameters of CRC patients. Univariate Cox regression analysis confirmed that tumor size (HR = 2.086, 95%CI = 1.131-3.848, $P = 0.019$), differentiation degree (HR = 5.299, 95%CI = 2.799-10.030, $P < 0.001$), T stage (HR = 4.469, 95%CI = 2.112-9.458, $P < 0.001$), N stage (HR = 2.630, 95%CI = 1.817-3.805, $P < 0.001$), M stage (HR = 3.396, 95%CI = 1.661-6.944, $P = 0.001$), TNM stage (HR = 2.520, 95%CI = 1.761-3.608, $P < 0.001$), and KIF20A expression (HR = 4.457, 95%CI = 1.877-10.579, $P = 0.001$) were significantly associated with worse prognosis in CRC patients. Multivariate Cox regression analysis also demonstrated that differentiation degree (HR = 5.138, 95%CI = 2.374-11.119, $P < 0.001$) and higher expression of KIF20A (HR = 2.803, 95%CI = 1.095-7.175, $P = 0.032$) were negatively correlated with OS (Table 3). Moreover, KIF20A expression was also an independent predictor of DFS (HR = 2.792, 95%CI = 1.311-5.946, $P = 0.008$) in CRC patients (Table 4). Collectively, these results indicated that a high KIF20A expression level was an independent prognostic factor in CRC patients.
3.3. Expression of KIF20A in CRC Cell Lines. Given the significant correlation between high expression of KIF20A and poor prognosis, we further analyzed the mRNA and protein expression of KIF20A among five CRC cell lines by RT-PCR and Western blot analysis, respectively (Figures 3(a) and 3(b)), and found that HCT116 and SW1116 had high expression of KIF20A, so they were chosen for subsequent study. To further identify the effect of KIF20A in CRC in vitro, siRNA transfection technology was used to silence its expression in the cell lines with high expression of KIF20A, and the transfection efficiency was detected by Western blot assays and RT-PCR (Figures 3(c) and 3(d)).

3.4. Knockdown of KIF20A Inhibits the Proliferation and Migration Ability of CRC Cells In Vitro. To explore the biological function of KIF20A in CRC progression, siRNA was transfected into CRC cell lines, and cell proliferation and migration ability were measured. The CCK-8 assay showed that cell proliferative activity was significantly decreased with KIF20A knockdown compared with that in control cells (Figure 4(a)). We also examined the effect of KIF20A on cell migration ability by wound healing and Transwell assays. Our data from the wound healing assay showed that the cell wound closure ability decreased after silencing KIF20A compared with that of the control group (Figure 4(b)). Transwell assays indicated that the migration of the si-KIF20A group was significantly reduced compared with that of the si-NC group (Figure 4(c)).

3.5. KIF20A Regulates the JAK/STAT3 Signaling Pathway. Previous studies have reported the important role of JAK/STAT3 signaling in CRC tumorigenesis [31, 32]. Hence, we examined whether there was a connection between KIF20A and JAK/STAT3 signaling. In this study, KIF20A knockdown reduced MMP2, phosphorylated JAK2, and phosphorylated STAT3 expression at the protein level (Figure 4(d)). These data imply that KIF20A could activate the JAK/STAT3 signaling pathway, which consequently promotes CRC carcinogenesis.

4. Discussion

Many investigators have found that overexpression of KIF20A plays a crucial role in tumorigenesis and cancer progression in various human cancers. KIF20A, a member of the kinesin superfamily, is characterized by a motor domain that is highly conserved in the evolution of biological species [33, 34]. KIF20A was first reported to localize to the Golgi apparatus, where it plays an important role in organelle dynamics with the GDP-bound form of Rab6 [8]. Moreover, KIF20A

---

Table 2: Oncomine analysis of KIF20A expression in colorectal cancer (total 9 colorectal cancer cohorts).

| Cohort no. | Cohort                                        | Sample (N)                          | t-test | Fold change | P value |
|-----------|-----------------------------------------------|-------------------------------------|--------|-------------|---------|
| 1         | Hong colorectal [23]                          | Colorectal carcinoma (70) vs. normal (12) | 10.005 | 2.891       | 7.36E−09 |
| 2         | Skrzypczak colorectal 2 [24]                  | Colon carcinoma (5) vs. normal (10)  | 9.362  | 5.046       | 1.49E−06 |
| 3         | Ki colon [25]                                 | Colon adenoma (5) vs. normal (10)   | 7.856  | 4.145       | 3.09E−06 |
| 4         | Skrzypczak colorectal [24]                    | Colon carcinoma epithelium (5) vs. normal (10) | 5.083  | 2.268       | 2.54E−04 |
| 5         | Graudens colon [26]                           | Colon adenoma epithelium (5) vs. normal (10) | 3.671  | 1.828       | 0.002   |
| 6         | Sabates-Bellver colon [27]                    | Rectal adenoma (7) vs. normal (32)   | 7.728  | 3.537       | 2.17E−05 |
| 7         | Kaiser colon [28]                             | Colon adenoma (25) vs. normal (32)   | 11.436 | 3.033       | 4.11E−16 |
| 8         | TCGA colorectal                                | Rectal mucinous adenocarcinoma (4) vs. normal (5) | 2.892  | 1.588       | 0.014   |
| 9         | Gaspar colon [29]                             | Colorectal carcinoma (18) vs. normal (12) | 3.397  | 1.308       | 0.001   |

---
Figure 2: Increased KIF20A protein expression predicts poor prognosis in patients with CRC. (a, b) IHC staining analysis of KIF20A protein levels in CRC patient tissues. (c, d) Kaplan-Meier analysis revealed that patients with higher KIF20A expression had worse OS and DFS than those with lower KIF20A expression ($P < 0.001$).
Table 3: Cox proportional hazard regression analysis for overall survival.

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR                  | 95% CI                | P value | HR | 95% CI | P value |
|                          | Lower               | Upper                |         | Lower | Upper |         |
| Gender                   | 1.393               | 0.743                | 2.477   | 0.320 |
| Age                      | 0.692               | 0.380                | 1.258   | 0.227 |
| Tumor size               | 2.037               | 1.131                | 3.848   | 0.019 |
| Differentiation degree   | 5.299               | 2.799                | 10.030  | <0.001| 5.138 | 2.374   | 11.119 | <0.001 |
| Tumor location           | 1.218               | 0.970                | 1.530   | 0.090 |
| T stage                  | 4.469               | 2.112                | 9.458   | <0.001|
| N stage                  | 2.630               | 1.817                | 3.805   | <0.001|
| M stage                  | 3.396               | 1.661                | 6.944   | 0.001 |
| TNM stage                | 2.520               | 1.761                | 3.608   | <0.001|
| KIF20A expression        | 4.457               | 1.877                | 10.579  | 0.001| 2.803 | 1.095   | 7.175  | 0.032 |

Abbreviations: HR: hazard ratio; CI: confidence interval.

Table 4: Cox proportional hazard regression analysis for disease-free survival.

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR                  | 95% CI                | P value | HR | 95% CI | P value |
|                          | Lower               | Upper                |         | Lower | Upper |         |
| Gender                   | 1.393               | 0.817                | 2.374   | 0.224 |
| Age                      | 0.798               | 0.469                | 1.356   | 0.404 |
| Tumor size               | 2.037               | 1.131                | 3.498   | 0.010 |
| Differentiation degree   | 3.788               | 2.077                | 6.912   | <0.001| 3.357 | 1.676   | 6.772  | 0.001 |
| Tumor location           | 1.180               | 0.974                | 1.530   | 0.091 |
| T stage                  | 3.591               | 1.876                | 6.876   | <0.001|
| N stage                  | 2.630               | 1.481                | 2.891   | <0.001|
| M stage                  | 3.396               | 1.661                | 6.944   | 0.001 |
| TNM stage                | 1.974               | 1.455                | 2.680   | <0.001|
| KIF20A expression        | 3.599               | 1.809                | 7.161   | <0.001| 2.792 | 1.311   | 5.946  | 0.008 |

Abbreviations: HR: hazard ratio; CI: confidence interval.

Figure 3: Expression of KIF20A in CRC cell lines. KIF20A expression was examined at the (a) mRNA and (b) protein levels in five CRC cell lines. The siRNA transfection efficiency was detected by (c) Western blot assays and (d) RT-PCR.
binds to microtubules and couples adenosine triphosphate hydrolysis to generate mechanical force [6], which is believed to play a central role in mitosis and cytokinesis [35]. KIF20A has been shown to accumulate in mitotic cells, which is involved in the formation of the mitotic spindle, and plays an important role in cytokinesis [9]. These results revealed that aberrant expression of KIF20A is closely associated with tumorigenesis.

A number of studies indicate that KIF20A is upregulated in many human malignant tumors. In the present study, we found that KIF20A was overexpressed in CRC tumors and associated with clinicopathological features and prognosis.
in CRC. TCGA cohort analysis revealed that the KIF20A mRNA expression level was significantly higher in CRC tissues than in normal tissues. Consistent with the KIF20A level in TCGA cohort, the data in the Oncomine database and from our center also further validated a higher level of KIF20A. In addition, our results showed that 64% of patients had high KIF20A expression in CRC tissues, and KIF20A expression was significantly associated with advanced T stage, N stage, M stage, and TNM stage. Moreover, overexpression of KIF20A was closely correlated with worse prognosis. This observation is similar to the recent finding in other tumors; it has been reported that KIF20A is an independent factor for overall survival (OS) and progression-free survival (PFS) in patients with nasopharyngeal carcinoma [13]. Zhang et al. revealed that overexpression of KIF20A was closely associated with many clinicopathological factors, including HPV infection, stage, recurrence, lymphovascular space involvement, nodal status, and poor prognosis in patients; moreover, upregulation of KIF20A also predicted poor OS and disease-free survival (DFS) in early cervical squamous cell carcinoma patients [36]. Based on the above findings, we found that KIF20A might play a role in cancer progression and serve as a novel biomarker of prognosis for CRC patients.

Invasion and metastasis are important biological characteristics of malignant tumors and are the pathological bases leading to tumor recurrence, disease deterioration, and death [37]. Zhao et al. confirmed that KIF20A is highly expressed in lung adenocarcinoma and may serve as an independent prognostic factor for OS. Moreover, knockdown of KIF20A could inhibit cell proliferation through G1 phase arrest and induce apoptosis [18]. In ovarian clear-cell carcinoma, high KIF20A expression may contribute to disease progression, which is principally attributable to its asymptomatic intraperitoneal dissemination with or without distant metastases to parenchymal organs [38]. A previous study showed that high expression of KIF20A can promote the proliferation, invasion, and migration of pancreatic cancer cells; in contrast, targeted silencing of KIF20A can reduce the proliferation, migration, and invasion [16]. Yamashita et al. found that KIF20A is a novel melanoma-associated antigen that may be considered to be a diagnostic and prognostic marker for melanoma [10]. Zou et al. demonstrated that KIF20A could be a potential new prognostic factor and target for endocrine therapy-resistant patients with breast cancer [12]. Consistent with the research described above, the results of this study confirmed that silencing KIF20A could inhibit the proliferation capacity of cells. Transwell and wound healing assays also showed that the migration ability of CRC cell lines was inhibited after knockdown of KIF20A. These data strongly suggest that KIF20A may act as an oncogene in the tumorigenesis and progression of CRC; however, its molecular mechanism in CRC is not yet clear.

JAK/STAT3 signaling pathway promotes the development of colon carcinoma cells [42]. Moreover, a previous report has illustrated that STAT3 targets MMP2 in cell migration and invasion of esophageal squamous carcinoma cells [43]. In the present study, KIF20A knockdown inhibited CRC cell proliferation and migration, which are related to reduced MMP2, phosphorylated JAK2, and phosphorylated STAT3 protein expression in CRC cells. Therefore, these observations indicate that KIF20A may promote CRC cell growth and migration through JAK/STAT3-dependent mechanisms and suggest that KIF20A can be further evaluated as a potential therapeutic target for CRC.

5. Conclusion

In summary, our data demonstrated that KIF20A was over-expressed in CRC tissues and was significantly associated with poor prognosis in patients with CRC. Silencing of KIF20A expression inhibited the proliferation and migration ability of CRC cell lines via the JAK/STAT3 signaling pathway. These data suggested that KIF20A is an important regulator in CRC progression, which may provide a new therapeutic target or clinical biomarker for treating patients with CRC.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Qi Zhang and Changjiang Qin conceived and designed the experiments. Qi Zhang, Jun Di, and Zhiyu Ji carried out the experiment of molecular biology and drafted the manuscript. Aoning Mi and Quanying Li carried out the cell experiment. Xianghui Du, Anpeng Wang, and Anlian Wang analyzed the data. All authors read and approved the final manuscript. Qi Zhang, Jun Di, and Zhiyu Ji contributed equally to this work.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (NSFC-U1504818), the Science and Technology Foundation of Henan Province (172102310152), the Natural Science Foundation of Henan Province of China (182300410359), the Medical Science and Technique Foundation of Henan Province (201601029), and the Education Foundation of Henan Province (19A320020).

References

[1] R. L. Siegel, K. D. Miller, S. A. Fedewa et al., “Colorectal cancer statistics, 2017,” CA: a Cancer Journal for Clinicians, vol. 67, no. 3, pp. 177–193, 2017.
Disease Markers

[2] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: a Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016.

[3] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2018,” CA: a Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7–30, 2018.

[4] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[5] E. Van Cutsem, A. Cervantes, B. Nordlinger, and D. Arnold, “Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 25, pp. iii–iii, 2014.

[6] N. Hirokawa, Y. Noda, and Y. Okada, “Kinesin and dynein superfamilies in organelle transport and cell division,” Current Opinion in Cell Biology, vol. 10, no. 1, pp. 60–73, 1998.

[7] N. Hirokawa, Y. Noda, Y. Tanaka, and S. Niwa, “Kinesin superfamly motor proteins and intracellular transport,” Nature Reviews. Molecular Cell Biology, vol. 10, no. 10, pp. 682–696, 2009.

[8] A. Echard, F. Jollivet, O. Martinez et al., “Interaction of a Golgi-associated kinesin-like protein with Rab6,” Science, vol. 279, no. 5350, pp. 580–585, 1998.

[9] E. Hill, M. Clarke, and F. A. Barr, “The Rab6-binding kinesin, Rab6-KIF1, is required for cytokinesis,” The EMBO Journal, vol. 19, no. 21, pp. 5711–5719, 2000.

[10] J. Yamashita, S. Fukushima, M. Jinnin et al., “Kinesin family member 20A is a novel melanoma-associated antigen,” Acta Dermato-Venereologica, vol. 92, no. 6, pp. 593–597, 2012.

[11] P. Khongkow, A. R. Gomes, C. Gong et al., “Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance,” Oncogene, vol. 35, no. 8, pp. 990–1002, 2016.

[12] J. X. Zou, Z. Duan, J. Wang et al., “Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance,” Molecular Cancer Research, vol. 12, no. 4, pp. 539–549, 2014.

[13] S. L. Liu, H. X. Lin, F. Qiu et al., “Overexpression of kinesin family member 20A correlates with disease progression and poor prognosis in human nasopharyngeal carcinoma: a retrospective analysis of 105 patients,” PLoS One, vol. 12, no. 1, p. e0169280, 2017.

[14] K. Taniuchi, M. Furihata, and T. Saibara, “KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells,” Neoplasia, vol. 16, no. 12, pp. 1082–1093, 2014.

[15] K. Imai, S. Hirata, A. Irie et al., “Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer,” British Journal of Cancer, vol. 104, no. 2, pp. 300–307, 2011.

[16] D. Stangel, M. Erkan, M. Buchholz et al., “Kif20a inhibition reduces migration and invasion of pancreatic cancer cells,” The Journal of Surgical Research, vol. 197, no. 1, pp. 91–100, 2015.

[17] I. Gasnerreau, M. Boissan, G. Margall-Ducos et al., “KIF20A mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis,” The American Journal of Pathology, vol. 180, no. 1, pp. 131–140, 2012.

[18] X. Zhao, L. L. Zhou, X. Li et al., “Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis,” Cancer Medicine, vol. 7, no. 9, pp. 4678–4689, 2018.

[19] G. Xiu, X. Sui, Y. Wang, and Z. Zhang, “FOXM1 regulates radiosensitivity of lung cancer cell partly by upregulating KIF20A,” European Journal of Pharmacology, vol. 833, pp. 79–85, 2018.

[20] M. B. Amin, S. B. Edge, F. L. Greene et al., American Joint Committee on Cancer. AJCC Cancer Staging Manual, pp. 113–123, Springer, New York, NY, 8th edition, 2017.

[21] C. J. Qin, X. M. Song, Z. H. Chen et al., “XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy,” Oncotarget, vol. 6, no. 31, pp. 32193–32204, 2015.

[22] D. Wang, S. Zhang, Y. Chen, B. Hu, and C. Lu, “Low expression of N KD2 is associated with enhanced cell proliferation and poor prognosis in human hepatocellular carcinoma,” Human Pathology, vol. 72, pp. 80–90, 2018.

[23] Q. Li, H. Tang, F. Hu, and C. Qin, “Knockdown of A-kinase anchor protein 4 inhibits hypoxia-induced epithelial-to-mesenchymal transition via suppression of the Wnt/β-catenin pathway in human gastric cancer cells,” Journal of Cellular Biochemistry, vol. 119, no. 12, pp. 10013–10020, 2018.

[24] Y. Hong, T. Downey, K. W. Eu, P. K. Koh, and P. Y. Cheah, “A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics,” Clinical & Experimental Metastasis, vol. 27, no. 2, pp. 83–90, 2010.

[25] M. Skrzypczak, K. Goryca, T. Rubel et al., “Correction: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability,” PLoS One, vol. 5, no. 12, 2010.

[26] D. H. Ki, H. C. Jeung, C. H. Park et al., “Whole genome analysis for liver metastasis gene signatures in colorectal cancer,” International Journal of Cancer, vol. 121, no. 9, pp. 2005–2012, 2007.

[27] E. Graudens, V. Boulanger, C. Mollard et al., “Deciphering cellular states of innate tumor drug responses,” Genome Biology, vol. 7, no. 3, p. R19, 2006.

[28] J. Sabates-Belver, L. G. van der Flier, M. de Palo et al., “Transcriptome profile of human colorectal adenomas,” Molecular Cancer Research, vol. 5, no. 12, pp. 1263–1275, 2007.

[29] S. Kaiser, Y. K. Park, J. L. Franklin et al., “Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer,” Genome Biology, vol. 8, no. 7, p. R131, 2007.

[30] C. Gaspar, J. Cardoso, P. Franken et al., “Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis,” The American Journal of Pathology, vol. 172, no. 5, pp. 1363–1380, 2008.

[31] M. L. Slattery, A. Lundgreen, S. A. Kadlubar, K. L. Bondurant, and R. K. Wolff, “JAK/STAT/SOCS-signaling pathway and colon and rectal cancer,” Molecular Carcinogenesis, vol. 52, no. 2, pp. 155–166, 2013.

[32] H. Xiong, Z. G. Zhang, X. Q. Tian et al., “Inhibition of JAK1/2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells,” Neoplasia, vol. 10, no. 3, pp. 287–297, 2008.
[33] R. D. Vale, T. S. Reese, and M. P. Sheetz, “Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility,” *Cell*, vol. 42, no. 1, pp. 39–50, 1985.

[34] N. Hirokawa and Y. Noda, “Intracellular transport and kinesin superfamliy proteins, KIFs: structure, function, and dynamics,” *Physiological Reviews*, vol. 88, no. 3, pp. 1089–1118, 2008.

[35] P. A. Nguyen, A. C. Groen, M. Loose et al., “Spatial organization of cytokinesis signaling reconstituted in a cell-free system,” *Science*, vol. 346, no. 6206, pp. 244–247, 2014.

[36] W. Zhang, W. He, Y. Shi et al., “High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma,” *PLoS One*, vol. 11, no. 12, p. e0167449, 2016.

[37] G. P. Gupta and J. Massague, “Cancer metastasis: building a framework,” *Cell*, vol. 127, no. 4, pp. 679–695, 2006.

[38] Y. Kawai, K. Shibata, J. Sakata et al., “KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear-cell carcinoma cells,” *Oncology Reports*, vol. 40, no. 1, pp. 195–205, 2018.

[39] H. Yu, H. Lee, A. Herrmann, R. Buettner, and R. Jove, “Revisiting STAT3 signalling in cancer: new and unexpected biological functions,” *Nature Reviews. Cancer*, vol. 14, no. 11, pp. 736–746, 2014.

[40] Q. Liang, D. Ma, X. Zhu et al., “RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer,” *Clinical Cancer Research*, vol. 24, no. 6, pp. 1473–1485, 2018.

[41] X. Xue, S. K. Ramakrishnan, K. Weisz et al., “Iron uptake via DMT1 integrates cell cycle with JAK-STAT3 signaling to promote colorectal tumorigenesis,” *Cell Meta*, vol. 24, no. 3, pp. 447–461, 2016.

[42] X. Xue, K. Jungles, G. onder, J. Samhoun, B. Györrfy, and K. M. Hardiman, “HIF-3α1 promotes colorectal tumor cell growth by activation of JAK-STAT3 signaling,” *Oncotarget*, vol. 7, no. 10, pp. 11567–11579, 2016.

[43] Y. Ou, L. Liu, L. Xue et al., “TRAP1 shows clinical significance and promotes cellular migration and invasion through STAT3/MMP2 pathway in human esophageal squamous cell cancer,” *Journal of Genetics and Genomics*, vol. 41, no. 10, pp. 529–537, 2014.